<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Infection and Immunity</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Infection and Immunity</journal-title><trans-title-group xml:lang="ru"><trans-title>Инфекция и иммунитет</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2220-7619</issn><issn publication-format="electronic">2313-7398</issn><publisher><publisher-name xml:lang="en">SPb RAACI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1440</article-id><article-id pub-id-type="doi">10.15789/2220-7619-III-1440</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>REVIEWS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОБЗОРЫ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Innate immunity in coronavirus infection</article-title><trans-title-group xml:lang="ru"><trans-title>Врожденный иммунитет при коронавирусной инфекции</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2723-1496</contrib-id><name-alternatives><name xml:lang="en"><surname>Smirnov</surname><given-names>V. S.</given-names></name><name xml:lang="ru"><surname>Смирнов</surname><given-names>В. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Vyacheslav S. Smirnov – PhD, MD (Medicine), Professor, Leading Researcher, Laboratory Molecular Immunology, St. Petersburg Pasteur Institute; Head Researcher, JSC MВSPC “Cytomed”</p><p>197101, St. Petersburg, Mira str., 14Phone: +7 911 948-59-22 (mobile) </p></bio><bio xml:lang="ru"><p>Смирнов Вячеслав Сергеевич – д.м.н., профессор, ведущий научный сотрудник лаборатории молекулярной иммунологии ФБУН НИИ эпидемиологии и микробиологии имени Пастера, главный научный сотрудник АО МБНПК «Цитомед»</p><p>197101, Санкт-Петербург, ул. Мира, 14Тел.: 8 911 948-59-22 (моб.) </p></bio><email>vssmi@mail.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4571-8799</contrib-id><name-alternatives><name xml:lang="en"><surname>Totolyan</surname><given-names>Areg A.</given-names></name><name xml:lang="ru"><surname>Тотолян</surname><given-names>Арег А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>RAS Full Member, PhD, MD (Medicine), Professor, Head of the Department of Immunology, Pavlov First St. Petersburg State Medical University; Director, St. Petersburg Pasteur Institute</p><p>St. Petersburg</p></bio><bio xml:lang="ru"><p>академик РАН, д.м.н., профессор, зав. кафедрой иммунологии ГБОУ ВПО Первый СанктПетербургский Государственный медицинский университет им. акад. И.П. Павлова МЗ РФ; директор ФБУН НИИ эпидемиологии и микробиологии имени Пастера, Санкт-Петербург</p></bio><email>totolian@pasteurorg.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">St. Petersburg Pasteur Institute</institution></aff><aff><institution xml:lang="ru">ФБУН НИИ эпидемиологии и микробиологии им. Пастера</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">JSC MBNPK “Cytomed”</institution></aff><aff><institution xml:lang="ru">АО МБНПК «Цитомед»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2020-05-22" publication-format="electronic"><day>22</day><month>05</month><year>2020</year></pub-date><volume>10</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>259</fpage><lpage>268</lpage><history><date date-type="received" iso-8601-date="2020-04-03"><day>03</day><month>04</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2020-04-06"><day>06</day><month>04</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2020, Smirnov V.S., Totolyan A.A.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2020, Смирнов В.С., Тотолян А.А.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="en">Smirnov V.S., Totolyan A.A.</copyright-holder><copyright-holder xml:lang="ru">Смирнов В.С., Тотолян А.А.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://iimmun.ru/iimm/article/view/1440">https://iimmun.ru/iimm/article/view/1440</self-uri><abstract xml:lang="en"><p>Coronaviruses (CoVs) comprise a polymorphic group of respiratory viruses causing acute inflammatory diseases in domestic and agricultural animals (chicken, pig, buffalo, cat, dog). Until recently, this infection in humans was mainly observed during the autumn-winter period and characterized by a mild, often asymptomatic, course. The situation changed dramatically in 2003, when SARS outbreak caused by pathogenic CoV (SARS-CoV) was recorded in China. A decade later, a new CoV outbreak occurred in the form of the Middle East respiratory syndrome (MERS-CoV), whereas in December 2019, SARS-CoV-2 (COVID-19) cases were recorded, which transformed within the first months of 2020 into the pandemic. In all three cases, CoV disease led to severe bronchopulmonary lesions, varying from dry, debilitating cough to acute respiratory distress syndrome (ARDS). At the same time, multiple changes in innate immunity were noted most often manifested as a pronounced inflammatory reaction in the lower respiratory tract, featured by damaged type II pneumocytes, apoptosis, hyalinization of alveolar membranes, focal or generalized pulmonary edema. Destructive processes in the respiratory tract were accompanied by migration of monocytes/macrophages and granulocyte neutrophils to the inflammatory focus. Such events were accompanied by production of pro-inflammatory cytokines, which magnitude could ascend up to a cytokine storm. SARS-CoV is characterized by symptoms of secondary immunosuppression, manifested by the late onset of interferon production and activation of NLRP3 inflammasomes – the key inflammatory factor. The reason for such reaction may be accounted for by CoV arsenal containing extensive set of structural and non-structural proteins exerting pro-inflammatory and immunosuppressive properties. Delayed IFN production allowed CoV to replicate actively and freely, and when type I IFN synthesis was eventually triggered, its activity was detrimental and accompanied by an aggravated infection course. Thus, SARS can surely be referred to immune-dependent infections with a marked immunopathological component. The purpose of this review was to describe some mechanisms underlying formation of innate immune response to infection caused by pathogenic coronaviruses SARS-CoV, MERS-CoV and SARS-CoV-2 (COVID-19).</p></abstract><trans-abstract xml:lang="ru"><p>Коронавирусы (CoV) представляют собой полиморфную группу респираторных вирусов, вызывающих острые воспалительные заболевания у домашних и сельскохозяйственных животных (куры, свиньи, буйволы, кошки, собаки). У людей инфекция до недавнего времени наблюдалось преимущественно в осенне-зимний период и характеризовалась легким, зачастую бессимптомным, течением. Ситуация резко изменилась в 2003 году, когда в Китае была зарегистрирована вспышка атипичной пневмонии, вызванная патогенным CoV (SARS-CoV). Спустя 10 лет возникла новая вспышка CoV в виде ближневосточного респираторного синдрома (MERS-CoV), а в декабре 2019 г. отмечены случаи SARS-CoV-2 (COVID-19), трансформировавшиеся в первые месяцы 2020 г. в пандемию. Во всех трех случаях заболевание часто приводило к тяжелыми бронхолегочными поражениями, варьировавшим от сухого изнурительного кашля до острого респираторного дистресс-синдрома (ОРДС). Одновременно с этим отмечены множественные изменения в системе врожденного иммунитета, чаще всего в виде выраженной воспалительной реакции в нижних дыхательных путях, проявлявшиеся повреждением пневмоцитов II порядка, явлениями апоптоза, гиалинизацией альвеолярных мембран, очаговым или генерализованным отеком легких. Деструктивные процессы в респираторном отделе сопровождались миграцией в очаг воспаления моноцитов/макрофагов и нейтрофильных гранулоцитов. На фоне перечисленных явлений наблюдалась выработка провоспалительных цитокинов, интенсивность которой могла нарастать до цитокинового шторма. Для SARS-CoV характерны симптомы вторичной иммунодепрессии, проявляющиеся в позднем начале синтеза интерферонов и активации ключевого фактора воспаления — NLRP3-инфламмасомы. Причиной подобной реакции является «вооруженность» CoV обширным набором структурных и неструктурных белков, обладающих провоспалительными и иммунодепрессивными свойствами. Отсроченный синтез IFN позволял вирусу активно и беспрепятственно реплицироваться, а когда все же организм запускал синтез IFN I, его действие оказывалось вредным и сопровождалось утяжелением течения инфекции. Таким образом, SARS можно с полным основанием отнести к числу иммунозависимых инфекций с выраженным иммунопатологическим компонентом. Цель этого обзора описать некоторые механизмы формирования врожденного иммунного ответа на инфицирование патогенными коронавирусами: SARS-CoV, MERS-CoV и SARS-CoV-2 (COVID-19).</p></trans-abstract><kwd-group xml:lang="en"><kwd>coronavirus</kwd><kwd>SARS-CoV</kwd><kwd>MERS-CoV</kwd><kwd>SARS-CoV-2</kwd><kwd>innate immunity</kwd><kwd>cytokines</kwd><kwd>intracellular regulatory cascade</kwd><kwd>interferons</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>коронавирус</kwd><kwd>SARS-CoV</kwd><kwd>MERS-CoV</kwd><kwd>SARS-CoV-2</kwd><kwd>врожденный иммунитет</kwd><kwd>цитокины</kwd><kwd>внутриклеточный регуляторный каскад</kwd><kwd>интерфероны</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>1. Никифоров В.В., Суранова Т.Г., Миронов А.Ю., Забозлаев Ф.Г. Новая коронавирусная инфекция (COVID-19): этиология, эпидемиология, клиника, диагностика, лечение и профилактика. Москва, 2020. 48 с.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>2. Смирнов В.С., Зарубаев В.В., Петленко С.В. Биология возбудителей и контроль гриппа и ОРВИ. СПб.: Гиппократ, 2020. 336 c.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>3. Amer H.M. Bovine-like Coronaviruses in domestic and wild ruminants Anim. Health Res. Rev., 2018, vol. 19, no. 2, pp. 113–124. doi: 10.1017/S1466252318000117</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>4. Ang A., Pullar J.M., Currie M.J., Vissers M.C.M. Vitamin C and immune cell function in inflammation and cancer. Biochem. Soc. Trans., 2018, vol. 46, no. 5, pp. 1147–1159. doi: 10.1042/BST20180169</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>5. Bowie A.G., O’Neill L.A.J. Vitamin C inhibits NF-κB activation by TNF via the activation of p38 mitogen-activated protein kinase. J. Immunol., 2000, vol. 165, pp. 7180–7188. doi: 10.4049/jimmunol.165.12.7180</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>6. Broz P., Dixit V.M. Inflammasomes: mechanism of assembly, regulation and signal-ling. Nat. Rev. Immunol., 2016, vol. 16, pp. 407–420. doi: 10.1038/nri.2016.58</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>7. Cameron M.J., Bermejo-Martin J.F., Danesh A., Muller M.P., Kelvin D.J. Human Immunopatho-genesis of Severe Acute Respiratory Syndrome (SARS). Virus Res., 2008, vol. 133, no. 1, pp. 13–19. doi: 10.1016/j.virusres.2007.02.014</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>8. Carr A.C., Maggini S. Vitamin C and immune function. Nutrients, 2017, vol. 9, no. 11, p. 1211. doi: 10.3390/nu9111211</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>9. Channappanavar R., Fehr A.R., Vijay R., Mack M., Zhao J., Meyerholz D.K., S. Perlman. Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice. Cell. Host. Microbe, 2016, vol. 19, no. 2, pp. 181–193. doi: 10.1016/j.chom.2016.01.007</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>10. Channappanavar R., Fehr A. R., Zheng J., Wohlford-Lenane C., Abrahante J.E., Mack M., Sompallae R., McCray P.B. Jr, Meyerholz D.K., Perlman S. IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes. J. Clin. Invest., 2019, vol. 129, no. 9, pp. 625–3639. doi: 10.1172/JCI126363</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>11. Channappanavar R. Perlman S. Pathogenic human coronavirus infections: causes and con-sequences of cytokine storm and immunopathology. Semin. Immunopathol., 2017, vol. 39, pp. 529–539. doi: 10.1007/s00281-017-0629</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>12. Chen I-Y., Moriyama M., Chang M.-F., Ichinohe T. Severe acute respiratory syndrome coronavirus viroporin 3a activates the NLRP3 inflammasome. Front. Microbiol., 2019, vol. 10, p. 50. doi: 10.3389/fmicb.2019.00050</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>13. Chien J.-Y., Hsueh P.-R., Cheng W.-C., Yu C.-J., Yang P.-C. Temporal changes in cytokine/chemokine profiles and pulmonary involvement in severe acute respiratory syndrome. Respirology, 2006, vol. 11, no. 6, pp. 715–722. doi: 10.1111/j.14401843.2006.00942.x</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>14. Cong Y., Hart B. J., Gross R., Zhou H., Frieman M., Bollinger L., Wada J. Hensley L.E., Jahrling P.B., Dyall J., Holbrook M.R. MERS-CoV pathogenesis and antiviral efficacy of licensed drugs in human monocyte-derived antigen-presenting cells. PLoS One, 2018, vol. 13, no. 3, pp. e0194868. doi 10.1371/journal.pone.0194868</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>15. Cui J., Li F., Shi Z.-L. Origin and evolution of pathogenic coronaviruses. Nat. Rev. Microbiol., 2019 vol. 17, pp. 181–192. doi: 10.1038/s41579-018-0118-9</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>16. DeDiego M.L., Nieto-Torres J.L. Jimenez-Guarde ño J.M, Regla-Nava J.A., Castaño-Rodriguez C., Fernandez-Delgado R., Usera F., Enjuanes L. Coronavirus virulence genes with main focus on SARS-CoV envelope gene. Virus Res., 2014, vol. 19, no. 194, pp. 124–137. doi: 10.1016/j.virusres.2014.07.024.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>17. Drosten C., G ünther S., Preiser W., van der Werf S., Brodt H.-R., Becker S., Rabenau H., Pan-ning M., Kolesnikova L., Fouchier R.A.M., Berger A., Burgui ère A.-M, Cinatl J., Eickmann M., Escriou N., Grywna K., Kramme S., Manuguerra J.-C., M üller S., Rickerts V., Stürmer M., Vieth S., Klenk H.-D., Osterhaus A.D.M.E., Schmitz H., Doerr H.W. Identification of a novel corona-virus in patients with severe acute respiratory syndrome. N. Engl. J. Med., 2003, vol. 348, no. 20, pp. 1967–1976. doi: 10.1056/NEJMoa030747</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>18. Feng B, Zhang Q, Wang J, Dong H., Mu X., Hu G., Zhang T. IFIT1 expression patterns induced by H9N2 virus and inactivated viral particle in human umbilical vein endothelial cells and bronchus epithelial cells. Mol. Cells, 2018, vol. 41, no. 4, pp. 271–281. doi: 10.14348/molcells.2018.2091.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>19. Gao J., Tian Z., Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci. Trends., 2020, vol. 14, no. 1, pp. 72–73. doi: 10.5582/bst.2020.01047</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>20. Grainger J., Boachie-Ansah G. Anandamide-induced relaxation of sheep coronary arter-ies: the role of the vascular endothelium, arachidonic acid metabolites and potassium channels. Br. J. Pharmacol., 2001, vol. 134, no. 5, pp. 1003–1012. doi: 10.1038/sj.bjp.0704340</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>21. Gralinski L.E., Bankhead III A., Jeng S., Menachery V.D., Proll S., Belisle S.E., Matzke M., Webb-Robertson B.-J.M., Luna M.L., Shukla A.K., Ferris M.T., Bolles M., Chang J., Aicher L., Waters K.M., Smith R.D., Metz T.O., Law G.L., Katze M.G., McWeeney S., Baric R.S. Mechanisms of severe acute respiratory syndrome coronavirus-induced acute lung injury. mBio., 2013, vol. 4, no 4: e00271-13. doi: 10.1128/mBio.00271-13</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>22. Gralinski L.E., Baric R.S. Molecular pathology of emerging coronavirus infections. J. Pathol., 2015, vol. 235, no. 2, pp. 185–195. doi: 10.1002/path.4454.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>23. Guo H., Callaway J.B., Ting J.P.-Y. Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat. Med., 2015, vol. 21, no. 7, pp. 677–687. doi: 10.1038/nm.3893</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>24. Guo Y.-R., Cao Q.-D., Hong Z.-S., Tan Y.-Y., Chen S.-D., Jin H.-J., K.-S. Tan, Wang D.-Y., Yan Y. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. Mil. Med. Res., 2020, vol. 7, no. 1, p 11. doi: 10.1186/s40779-020-00240-0</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>25. He Y., Hara H., N úñ ez G. Mechanism and regulation of NLRP3 inflammasome activation. Trends Biochem. Sci., 2016, vol. 4, no. 12, pp. 1012–1021 doi: 10.1016/j.tibs.2016.09.002</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>26. Hemil ä H. Vitamin C and Infections. Nutrients, 2017, vol. 9, no. 4, p. 339. doi: 10.3390/nu9040339.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>27. Hemil ä H., Chalker E. Vitamin C for preventing and treating the common cold. Cochrane Database Syst. Rev., 2013, no. 1: CD000980. doi: 10.1002/14651858.CD000980.pub4</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>28. Hendrickson C.M., Matthay M.A. Viral pathogens and acute lung injury: investigations inspired by the SARS epidemic and the 2009 H1N1 influenza pandemic. Semin. Respir. Crit. Care Med., 2013, vol. 34, no. 4, pp. 475–486. doi: 10.1055/s-0033-1351122.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>29. Hornung V., Latz E. Critical functions of priming and lysosomal damage for NLRP3 activation. Eur. J. Immunol., 2010, vol. 40, pp. 20–623. doi: 10.1002/eji.200940185.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>30. Humphries E.S.A., Dart C. Neuronal and cardiovascular potassium channels as therapeutic drug targets. J. Biomol. Screen., 2015, vol. 20, no. 9, pp. 1055–1073. doi: 10.1177/1087057115601677</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>31. Ishiguro T., Kobayashi Y., Uozumi R., Takata N., Takaku Y., Kagiyama N., Kanauchi T., Shimizu Y., Takayanagi N. Viral pneumonia requiring differentiation from acute and progressive diffuse interstitial lung diseases. Intern. Med., 2019, vol. 58, no. 24, pp. 3509–3519. doi: 10.2169/internalmedicine.2696-19</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>32. Jacobs S.R., Damania B. NLRs, inflammasomes, and viral infection. J. Leukoc. Biol., 2012, vol. 92, no. 3, pp. 469–477. doi: 10.1189/jlb.0312132</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>33. Khomich O.A., Kochetkov S.N., Bartosch B. Ivano A.V. Redox biology of respiratory viral infections. Viruses, 2018, vol. 10, no. 8, pp. 392. doi: 10.3390/v10080392.</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>34. Kim E.S., Choe P.G., Park W.B., Oh H.S., Kim E.J., Nam E.Y., Na S.H., Kim M. Song K.H., Bang J.H., Park S.W., Kim H.B., Kim N.J., Oh M.D. Clinical progression and cytokine profiles of middle east respiratory syndrome coronavirus infection. J. Korean Med. Sci., 2016, vol. 31, no. 11, pp. 1717–1725. doi: 10.3346/jkms.2016.31.11.1717</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>35. Kopecky-Bromberg S.A., Martinez-Sobrido L., Frieman M., Baric R.A., Palese P. Severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and nucleocapsid proteins function as interferon antagonists. J. Virol., 2007, vol. 81, no. 2, pp. 548–557. doi: 10.1128/JVI.01782-06.</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>36. Kuhn J.H., Li W., Choe H., Farzan M. Angiotensin-converting enzyme 2: a functional receptor for SARS coronavirus. Cell Mol. Life Sci., 2004, vol. 61, no. 21, pp. 2738–43. doi: 10.1007/s00018-004-4242-5</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>37. Latz E., Xiao T.S., Stutz A. Activation and regulation of the inflammasomes. Nat. Rev. Immunol., 2013, vol. 13, pp. 397–411. doi: 10.1038/nri3452</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>38. Li G. Fan Y. Lai Y. Han T., Li Z., Zhou P., Pan P., Wang W., Hu D., Liu X., Zhang Q., Wu J. Coronavirus infections and immune responses. J. Med. Virol., 2020, vol. 92, pp. 424–432. doi: 10.1002/jmv.25685</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>39. Li S., Yuan L., Dai G., Chen R.A., Liu D.X., Fung T.S. Regulation of the ER stress response by the ion channel activity of the infectious bronchitis coronavirus envelope protein modulates virion release, apoptosis, viral fitness, and pathogenesis. Front. Microbiol., 2020, vol. 10, p. 322. doi: 10.3389/fmicb.2019.03022</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>40. Lui P.-Y., Wong L.-Y. R., Fung C.-L., Siu K.-L., Yeung M.-L., Yuen K.-S., Chan C.-P., Woo P.C.-Y., Yuen K.-Y., Jin D.-Y. Middle East respiratory syndrome corona-virus M protein suppresses type I interferon expression through the inhibition of TBK1dependent phosphorylation of IRF3. Emerg. Microbes Infect., 2016, vol. 5, no. 4: e39. doi: 10.1038/emi.2016.33</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>41. Mackay I.M., Arden K.E. MERS coronavirus: diagnostics, epidemiology and transmission. Virol. J., 2015, vol. 12, p. 222. doi: 10.1186/s12985-015-0439-5</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>42. Marku š i ć M., Š antak M., Ko š uti ć -Gulija T., Jergovi ć M., Jug R., For č i ć D. Induction of IFN-α subtypes and their antiviral activity in mumps virus infection. Viral Immunol., 2014, vol. 27, no. 10, pp. 497–505. doi: 10.1089/vim.2014.0028</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>43. Marmolejo-Murillo L.G., Ar é chiga-Figueroa I.A., Cui M., Moreno-Galindo E.G., Navarro-Polanco R.A., S á nchez-Chapula J.A., Ferrer T., Rodr íguez-Menchaca A.A. Inhibition of Kir4.1 potassium channels by quinacrine. Brain Res., 2017, vol. 1663, pp. 87–94. doi: 10.1016/j.brainres.2017.03.009</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>44. Mart ín-Vicente M., Medrano L.M., Resino S., García-Sastre A., Martínez I. TRIM25 in the regulation of the antiviral innate immunity. Front. Immunol., 2017, vol. 8, p. 1187. doi: 10.3389/fimmu.2017.01187</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>45. Menachery V.D., Mitchell H.D., Cockrell A.S., Gralinski L.E., Yount B.L. Jr, Graham R.L., McAnarney E.T., Douglas M.G., Scobey T., Beall A., Dinnon 3 rd K., Kocher J.F., Hale A.E., Stratton K.G., Waters K.M., Baric R.S. MERS-CoV accessory ORFs play key role for infection and pathogenesis. mBio, 2017, vol. 8, no. 4. doi: 10.1128/mBio.00665-17</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>46. Mubarak A., Alturaikiand W., Hemida M.G. Middle East respiratory syndrome coronavirus (MERS-CoV): infection, immunological response, and vaccine development. J. Immunol. Res., 2019, p. 6491738. doi: 10.1155/2019/6491738.</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>47. Mu ñ oz-Planillo R., Kuffa P., Mart í nez-Col ó n G., Smith B.L., Rajendiran T.M., N úñ ez G. K+ efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate. Matter. Immunity, 2013, vol. 38, no. 6, pp. 1142–1153. doi: 10.1016/j.immuni.2013.05.016</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>48. Murakami T., Ockinger J., Yu J., Byles V., McColl A., Hofer A.M., Horng T. Critical role for calcium mobilization in activation of the NLRP3 inflammasome. Proc. Natl. Acad. Sci. USA, 2012, vol. 109, pp. 11282–11287. doi: 10.1073/pnas.1117765109</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation>49. Narayanan K., Huang C., Makino S. SARS coronavirus accessory proteins. Virus Res., 2008, vol. 133, no. 1, pp. 113–121. doi: 10.1016/j.virusres.2007.10.009</mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation>50. Nelemans T., Kikkert M. Viral Innate immune evasion and the pathogenesis of emerging RNA virus infections. Viruses, 2019, vol. 11, no. 10, p. 961. doi: 10.3390/v11100961</mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation>51. Nieto-Torres J. L., Verdiá-Báguena C., Jimenez-Guardeño J.M., Regla-Nava J.A., Castaño-Rodriguez C., Fernandez-Delgado R., Torres J., Aguilella V.M., Enjuanes L. Severe acute respiratory syndrome coronavirus e protein transports calcium ions and activates the NLRP3 inflammasome. Virology, 2015, vol. 485, pp. 330–339. doi: 10.1016/j.virol.2015.08.010</mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation>52. Prompetchara E., Ketloy C., Palaga T. Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic. Asian Pac. J. Allergy Immunol., 2020, vol. 38, no. 1, pp. 1–9. doi: 10.12932/AP-200220-0772</mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation>53. Rathinam V.A.K., Chan F.K.-M. Inflammasome, inflammation and tissue homeostasis. Trends. Mol. Med., 2018, vol. 24, no. 3, pp. 304–318. doi: 10.1016/j.molmed.2018.01.004</mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation>54. Shi C.-S., Qi H.-Y., Boularan C., Huang N.-N., Abu-Asab M., Shelhamer J.H., Kehrl J.H. SARS-CoV ORF9b suppresses innate immunity by targeting mitochondria and the MAVS/TRAF3/TRAF6 signalosome. J. Immunol., 2014, vol. 193, no. 6, pp. 30803089. doi: 10.4049/jimmunol.1303196</mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation>55. Shokri S., Mahmoudvand S., Taherkhani R., Farshadpour F. Modulation of the immune response by middle east respiratory syndrome coronavirus. J. Cell. Physiol., 2019, vol. 234, no. 3, pp. 2143–2151. doi: 10.1002/jcp.27155</mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation>56. Silva da Costa L., Outlioua A., Anginot A., Akarid K., Arnoult D. RNA viruses promote activation of the NLRP3 inflammasome through cytopathogenic effect-induced potassium efflux. Cell Death Dis., 2019, vol. 10, no. 5, p. 346. doi: 10.1038/s41419-019-1579-0</mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation>57. Simmons G., Zmora P., Gierer S., Heurich A., P öhlmann S,. Proteolytic activation of the SARS-coronavirus spike protein: Cutting enzymes at the cutting edge of antiviral research. Antiviral Res., 2013, vol. 100, no. 3, pp. 605–614. doi: 10.1016/j.antiviral.2013.09.028</mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation>58. Singhal T.A Review of coronavirus disease-2019 (COVID-19). Indian J. Pediatr., 2020, vol. 87, no. 4, pp. 281–286. doi: 10.1007/s12098-020-03263-6</mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation>59. Song Z., Xu Y., Bao L., Zhang L., Yu P., Qu Y., Zhu H., Zhao W., Han Y., Qin C. From SARS to MERS, thrusting coronaviruses into the spotlight. Viruses., 2019, vol. 11, no. 1: 59. doi: 10.3390/v11010059</mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation>60. Su S., Wong G., Shi W., Liu J., Lai A.C.K., Zhou J., Liu W., Bi Y., Gao G.F. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol., 2016, vol. 24, no. 6, pp. 490–502. doi 10.1016/j.tim.2016.03.003</mixed-citation></ref><ref id="B61"><label>61.</label><mixed-citation>61. Thiel V., Weber F. Interferon and cytokine responses to SARS-coronavirus infection. Cytokine Growth Factor Rev., 2008, vol. 19, no. 2, pp. 121–132 doi.10.1016/j.cytogfr.2008.01.001</mixed-citation></ref><ref id="B62"><label>62.</label><mixed-citation>62. Tykocki N.R., Boerman E.M., Jackson W.F. Smooth muscle ion channels and regulation of vascular tone in resistance arteries and arterioles. Compr. Physiol., 2017, vol. 7, no. 2, pp. 485–581. doi: 10.1002/cphy.c160011</mixed-citation></ref><ref id="B63"><label>63.</label><mixed-citation>63. Tynell J., Westenius V., R ö nkk ö E. , Munster V.J., Mel é n K., Ö sterlund P., Julkunen I. Middle East respiratory syndrome coronavirus shows poor replication but significant induction of antiviral responses in human monocyte-derived macrophages and dendritic cells. J. Gen. Virol., 2016, vol. 97, no. 2, pp. 344–355. doi: 10.1099/jgv.0.000351</mixed-citation></ref><ref id="B64"><label>64.</label><mixed-citation>64. Van der Meer Y., van Tol H., Locker J.K., Snijder E.J. ORF1a-encoded replicase subunits are involved in the membrane association of the arterivirus replication complex. J. Virol., 1998, vol. 72, no. 8, pp. 6689–6698. PMID: 9658116</mixed-citation></ref><ref id="B65"><label>65.</label><mixed-citation>65. Wang K., Chen W., Zhou Y.-S., Lian J.-Q., Zhang Z., Du P., Gong L., Zhang Y., Cui H.-Y., Geng J.-J., Wang B., Sun X.-X., Wang C.-F., Yang X., Lin P., Deng Y.-Q., Wei D., Yang X.-M., Zhu Y.-M., Zhang K., Zheng Z.-H., Miao J.-L., Guo T., Shi Y., Zhang J., Fu L., Wang Q.-Y., Bian H., Zhu P., Chen Z.-N. SARS-CoV-2 invades host cells via a novel route: CD147-spike protein. Preprint, 2020. doi: 10.1101/2020.03.14.988345</mixed-citation></ref><ref id="B66"><label>66.</label><mixed-citation>66. Wang Y., Shi P., Chen Q., Huang Z., Zou D., Zhang J., Gao X., Lin Z. Mitochondrial ROS promote macrophage pyroptosis by inducing GSDMD oxidation. J. Mol. Cell Biol., 2019, vol. 11, no. 12, pp. 1069–1082. doi: 10.1093/jmcb/mjz020</mixed-citation></ref><ref id="B67"><label>67.</label><mixed-citation>67. Xu X., Chen P., Wang J., Feng J., Zhou H., Li X., Zhong W., Hao P. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci. China Life Sci., 2020, vol. 63, no. 3, pp. 457–460. doi: 10.1007/s11427-020-1637-5</mixed-citation></ref><ref id="B68"><label>68.</label><mixed-citation>68. Yue Y., Nabar N. R., Shi C.-S., Kamenyeva O., Xiao X., Hwang I.-Y., Wang M., Kehrl J.H. SARS-coronavirus open reading frame-3a drives multimodal necrotic cell death. Cell Death Dis., 2018, vol. 9, no. 9, p. 904. doi: 10.1038/s41419-018-0917-y</mixed-citation></ref><ref id="B69"><label>69.</label><mixed-citation>69. Zhao C., Zhao W. NLRP3 Inflammasome — a key player in antiviral responses. Front. Immunol., 2020, vol. 11, p. 211. doi: 10.3389/fimmu.2020.00211</mixed-citation></ref><ref id="B70"><label>70.</label><mixed-citation>70. Zumla A., Chan J.F.W., Azhar E.I. Coronaviruses — drug discovery and therapeutic options. Nat. Rev. Drug Discov., 2016, vol. 15, no. 5, pp. 327–347. doi: 10.1038/nrd.2015.37</mixed-citation></ref></ref-list></back></article>
